Case Studies
G-Rex: Expanding the Capabilities of Scalability
When global events affected the availability of products used in the manufacture
of cell therapies, teams needed to explore alternative manufacturing methods. This supply chain crisis emphasized the need to establish redundant processes to address production obstacles for critical stages of cell therapy manufacturing.
Scientific Posters
TcBuster transposase for robust delivery of multicistronic therapeutic cargo - Scientific Poster
TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.
Scientific Posters
Feeder-Free Human iNK Differentiation Process - Scientific Poster
Current iNK differentiation protocols typically utilize xenogenic feeder cells, which could be problematic for patient safety, or they lack robustness and are highly variable in differentiation efficiency. Using animal-free small molecules and recombinant proteins, Bio-Techne developed a feeder-free differentiation process to reliably generate iNKs at scale by optimizing for CD34+ hematopoietic stem cells (iHSC) prior to downstream NK differentiation.
Protocols
ExCellerate NK Media Feeder-Cell G-Rex Culture Process
Download the ExCellerate NK Media Feeder-Cell G-Rex Culture Process
Protocols
ExCellerate NK Media Feeder-Free G-Rex Culture Protocol
Download the protocol to support a feeder-free process in G-Rex cell culture.
Literature
ExCellerate NK Media Flyer
ExCellerate NK Media offers a robust and versatile solution for NK cell cultures, designed to transition from research to clinical application seamlessly.
Literature
Liquid Cytokines Brochure
Streamline your cell culture process with our new liquid frozen formulations of animal-free RUO and GMP IL-2, IL-7, and IL-15. These ready-to-use cytokines eliminate reconstitution errors while still providing the same potency and consistency as our lyophilized proteins. Simply thaw and add to your cell culture.
Application Notes
CAR NK-92 cell–mediated depletion of residual TCR+ cells
Utilization of G-Rex by introducing a new scalable depletion method: Coculturing target CAR T cells with an NK-92 cell line in G-Rex to purify their CAR T cells and promote CAR T cell expansion at the same time.
Publications
Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma
This study presents a protocol for large-scale expansion of NKG2C+ NK cells using PC-3 feeder cells. G-Rex 6M well plates were employed to achieve high expansion factors (median 358.5-fold) of functional NK cells for glioblastoma immunotherapy.
Webinars
Marker TX T-cell Manufacturing Simplification
Join Anastasiya Smith, Snr. Director of R&D at Marker Therapeutics for a 15-minute pre-recorded webinar covering the first critical steps in successful automation through simplification with the G-Rex platform.
Literature
Proven Process
This is our proven process illustrating how ScaleReady works in a true partnership with your T and NK cell therapy program to enable the successful commercialization of your drug. This is a linear left-to-right, as well as a holistic view, of how at every stage, we look to simplify, streamline, and scale by offering expertise and support for your cell therapy program. Through our proven process, we deliver practical and viable solutions by providing the most simple, scalable, and versatile manufacturing products. Our process is proven, as our products are represented in approved CAR-T drugs around the globe.
Literature
RUO and GMP IL-2 Cytokine Brochure
GMP Recombinant Human IL-2 joins IL-7 and IL-15 produced within Bio-Techne’s dedicated animal-free GMP facility located in St. Paul MN USA. Our GMP-grade IL-2 contains the same cysteine to serine mutation found in Proleukin®. This mutation has been reported to prevent cysteine mispairing in E.coli, which can lead to protein aggregation and makes our new GMP-grade IL-2 protein soluble in injectable-grade water.